GSK, Teva Urge High Court To Review Pay-For-Delay Accords
GlaxoSmithKline and Teva urged the U.S. Supreme Court on Wednesday to review their challenge of a Third Circuit decision allowing a pay-for-delay case over the seizure drug Lamictal to move forward,...To view the full article, register now.
Already a subscriber? Click here to view full article